CDC report on Covid vaccine benefits delayed by acting director

Jay Bhattacharya, the acting CDC director, has delayed the publication of a report that demonstrates the benefits of the Covid vaccine, which reportedly found a significant reduction in emergency room visits and hospitalizations among vaccinated healthy adults. The report, initially set for publication on March 19, is under review due to concerns about its methodology. According to the Washington Post, the CDC's research indicated that the vaccine cut the likelihood of Covid-related hospitalizations by 55% and emergency visits by 50% during the winter months.

This delay has sparked alarm among experts and former CDC officials, who fear it reflects a broader strategy by the Trump administration to undermine vaccine-related research. Dr. Fiona Havers, a former senior adviser on vaccine policy at the CDC, stated, "This is definitely an escalation of this administration’s undermining of CDC science." Havers, who resigned last year in protest of the administration's vaccine policy, emphasized that the methodology in question has been standard for CDC studies for nearly two decades.

Health Secretary Robert F. Kennedy Jr., a vocal critic of Covid vaccines, has been accused of employing both public and covert tactics to diminish the credibility of vaccine research. The administration's actions come as it seeks to reshape public perception of Covid-19 vaccines ahead of the 2026 midterms. Havers noted, "The report said something that this administration doesn’t want to have publicized – that the Covid vaccines are effective at preventing severe illness."

The CDC has defended the review process, stating that it is routine for leadership to assess concerns about methodology prior to publication. However, the political implications of this delay raise questions about the integrity of health communications from the CDC under the current administration. The ongoing shakeup within the Department of Health and Human Services, marked by Kennedy's controversial appointments and firings, further complicates the landscape of public health policy.

What to watch: The upcoming decision on whether to publish the delayed report could signal the administration's stance on vaccine efficacy as midterm elections approach.